Purpose: Diabetes is a chronic lifelong condition, and adherence to medications and self-monitoring of blood glucose are challenging for diabetic patients. The dramatic increase in the prevalence of diabetes is largely due to the incidence of type 2 diabetes in low-and middle-income countries (LMIc) besides high-income countries (HIc). We aimed to evaluate whether pharmacist care (PC) service model in LMIc and HIc could improve clinical outcomes in diabetic patients by performing a meta-analysis. Methods: PubMed, Embase, and ProQuest Dissertations Unlimited Published Literature database were searched to find publications pertaining to pharmacist-led intervention in patients with diabetes. The inclusion criteria were as follows: 1) randomized controlled trials, 2) confirmed diabetic patients (type 1 or type 2), 3) pharmaceutical care intervention by clinical pharmacist or/and multidisciplinary team, and 4) reporting HbA1c at baseline and end of study or the mean change in these values. Results: A total of 37 articles were included in the meta-analysis. The overall result was significant and in favor of PC intervention on HbA1c change (standard difference in mean values [SDM]: 0.379, 95% CI: 0.208-0.550, P0.001). The stratified meta-analysis showed that PC was significant in both HIc (n=20; SDM: 0.351, 95% CI: 0.207-0.495) and LMIc (n=15; SDM: 0.426, 95% CI: 0.071-0.780). More than 6 months is needed to obtain adequate effects on clinical diabetes parameters. Conclusion: Our study presented that an adequate duration of pharmacist-led pharmaceutical care was effective in improving HbA1c in patients with diabetes in both LMIc and HIc.
Introduction
Diabetes is a serious and chronic disease that can lead to various complications and premature death. According to the "Global Report on Diabetes (2016)" by World Health Organization (WHO), the number of diabetic adults has quadrupled to 422 million since 1980. This recent dramatic rise is largely due to the incidence of type 2 diabetes in low-and middle-income countries (LMIc). In all, 43% of deaths in a total or 3.7 million deaths related to diabetes in 2012 is attributable to higher than optimal blood glucose, and this occurs before the age of 70, 1 which is much shorter than the life expectancy of 81.3 mean years among the Organisation for Economic Co-operation and Development (OECD) countries in 2015. 2 Since diabetes is a chronic lifelong condition, adherence to medications and self-monitoring of blood glucose are quite challenging to the patients. Blood glucose concentration is a sensitive marker submit your manuscript | www.dovepress.com
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Jeong et al affected by numerous outer environments such as food intake, exercise, stress and medication. 3 On the contrary, HbA1c concentration in the blood reflects the average blood glucose over the previous [8] [9] [10] [11] [12] weeks. The HbA1c level can predict the clinical outcome of microvascular 4, 5 and macrovascular complications 6 as well, and the American Diabetes Association (ADA) recommend that HbA1c should be measured at regular intervals in all patients with diabetes. 7 Thus, many researches on diabetes management are using HbA1c as a surrogate marker for clinical outcomes. There have been numerous efforts to implement pharmaceutical care in diabetic patients to improve disease outcomes. Improved management with the consistent support of multidisciplinary pharmaceutical care services can lead to better control of diabetes and fewer complications. 8 For example, in Medication Therapy Management (MTM), a range of services including education, counseling, and assessing each medication and medication-related problems are provided to patients by clinical pharmacists to optimize and improve therapeutic outcomes in the USA. 9 Together with hospital-based clinician-monitored programs, pharmacist-led community/ hospital-based pharmaceutical care programs can be designed in an effort to achieve better glycemic, metabolic outcome and blood pressure control in this patient group. 10 A recent meta-analysis 11 and a systematic review 12 of pharmacist for blood pressure and cardiovascular diseases showed that the implementation of a pharmacist care (PC) model provided improvement in outcomes. The systematic analysis and meta-analysis of PC for diabetic patients showed positive impact on HbA1c outcomes. [13] [14] [15] However, recent studies reported no significantly different clinical parameters between the PC group and usual care (UC) group, [16] [17] [18] rendering the need to reevaluate PC. Moreover, they did not present the effectiveness of PC in LMIc apart from high-income countries (HIc). Since the 2016 report of WHO revealed a considerable increase in the number of diabetic patients in LMIc, thus we aimed to evaluate whether the PC service model in HIc and LMIc could improve the clinical outcomes of diabetic patients by performing a meta-analysis including the up-to-date studies.
Methods
search strategy
A systematic review protocol conforming to the Effective Practice and Organization of Care (EPOC) guideline was developed and prepared following the PRISMA recommendations. 19 Electronic databases of PubMed, Embase, and ProQuest Dissertations Unlimited Published Literature database were searched by using the following keywords: "diabetes", "diabetes mellitus", "type one diabetes", "type two diabetes", "diabetes type 1", "diabetes type 2", "community pharmacy", "community pharmacies", "community pharmacist", "community pharmacists", "pharmacy", "pharmacist", "hospital pharmacy", "hospital pharmacist", "hospital pharmacists", "pharmacy services", "pharmacist intervention", "pharmaceutical care", "pharmac*". A manual review was performed to search for unindexed articles in inclusion and exclusion criteria
The literature search was performed to include studies published up to July 27, 2017, by two independent reviewers. Any disagreement was resolved by discussion among the two reviewers and a third researcher. The inclusion criteria for full-text review were as follows: 1) randomized controlled trial (RCT); 2) confirmed adult diabetic patients (type 1 or type 2); 3) pharmaceutical care intervention by clinical pharmacist or/and multidisciplinary team (PC includes working in cooperation with the patient and other health care providers to assess, monitor, initiate, and modify medication use and to provide education service to health care professionals as well as to the patients); and 4) each article should have reported HbA1c or fasting blood glucose (FBG) level at baseline and end of study or the mean change in these values. The exclusion criteria were as follows: non-English language, editorials, commentaries, narrative reviews, clinical practice guidelines, conference abstracts, and literature not in peer-reviewed journals. The same reviewers independently evaluated the full text of all identified studies in the first stage of screening and resolved any disagreements.
Outcome assessment
HbA1c concentration in the blood reflects the average blood glucose over the previous 8-12 weeks. The HbA1c level can predict the clinical outcome of microvascular 4, 5 and macrovascular complications 6 as well, and ADA recommend HbA1c to be measured at regular intervals in all patients with diabetes. 7 Thus, HbA1c has been utilized as an additional stable criterion for assessing glucose control. In this aspect, we chose the difference of HbA1c change and the proportion of patients achieving target HbA1c level (7%) between two groups as the main outcome measure. 
Data extraction
The following information was extracted from the full text of included studies by two independent researchers: first author, year of publication, study type, country of study site, disease type of patients, age, service providers, intervention type, and laboratory data pertaining to HbA1c and the number of patients achieving HbA1c goal. The income levels were searched to pool outcomes by income level using the data from the World Bank Group. 20 The duration of intervention was stratified and designated as 1 (6 months), 2 (6 and 12 months), and 3 (12 months).
Quality score assessment
The quality of individual study was assessed by two independent reviewers using the EPOC risk of bias tool. This risk of bias tool is used when the clinical trials involve patient care, educational intervention, patient performance measure, health care quality measure. 21 The standard risk of bias tool includes assessment of domains such as allocation concealment, baseline outcome, baseline characteristics, blinding, and selective reporting.
A domain with a low risk of bias is indicated by "low" and that with a high risk of bias is indicated by "high". If a particular domain has ambiguity or uncertainty due to lack of information, then it is indicated as "unclear".
statistical analyses
The association between HbA1c levels after PC intervention and clinical outcomes was evaluated quantitatively by meta-analysis. The pooled OR were calculated for the included articles stratified by income status of the countries and duration of follow-up (3-5 months, 6-11 months, and 12 months). The primary outcome of this study was to evaluate the association between PC and HbA1c change.
Between-study heterogeneity was assessed by Q-statistic (heterogeneity was considered statistically significant if P0.1) 22 and quantified by I 2 value. Both fixed-and random-effects models were used to combine the aggregate data determined by the I 2 value. When I 2 was 50%, the random-effects model was used for analysis. Potential publication bias was assessed using the Egger's linear regression test. 23 Statistical analyses were performed using Comprehensive Meta-Analysis (ver 3; Biostat, Inc., Engelwood, NJ, USA) and IBM SPSS (ver 21; IBM Corporation, Armonk, NY, USA). All tests were two sided, and P0.05 was considered as significant unless otherwise specified.
Results
PRISMA flow for study selection
As shown in Figure 1 , of the 3,794 publications identified, 35 publications were found eligible for meta-analysis.
Among the identified publications, 3,465 articles were excluded as inappropriate by title and abstract review. In all, 82 articles were eligible for full-text review. After excluding studies with no pharmacist intervention (n=2), inadequate information (n=10), non-RCT studies (n=41), and non-adult studies (n=2), 27 articles were finally selected. Upon searching for the reference review, 10 additional articles were found to be eligible for meta-analysis; therefore finally, 37 studies were included in the meta-analysis.
Overall review
In all, 14 20 The intervention period was stratified as follows: intervention period 6 months (n=7), between 6 and 12 months (n=10), and 12 months (n=12). All the trials were conducted in ambulatory settings, including private clinic, hospital-based clinic, community pharmacies, and nationwide health care system or regional health care system (Table 1 ).
All 37 studies included 2,961 PC and 2,899 UC patients. The overall period of pharmacist intervention was mean 9.07 months (SD 5.73) ranging from 3 to 32 months. In 27 studies, 100 diabetic patients were enrolled, and in 15 studies, the follow-up period was 12 months. The interventions were given from 2-week to 3-month interval, and several studies did not report the interval. The PC was conducted by pharmacists in 24 studies and MTC in 13 studies. The PC program consisted of information on disease and medications, adherence education, survival skills regarding hypo-and hyperglycemia incidence, and insulin injection skills. The delivery type of education or intervention was face-to-face intervention, telephone counseling, or group appointments, meeting, or education sessions. Adjunctive tools such as booklets, disease or medication information sheets, pillbox, and stickers were provided in many studies ( Table 1) .
The overall pooled analysis for HbA1c change included 35 articles out of total 37 studies (Table S1 ). Owing to the submit your manuscript | www.dovepress.com
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The proportion of patients achieving HbA1c goals was evaluated using eight articles that reported targeted outcomes out of total 37 included studies (Table S2 ). All the seven studies set the HbA1c target 7%, and the pooled result for the Figure 3 ).
group analysis for income status and intervention period
The stratified meta-analysis showed that PC was significant in both 20 HIc (SDM: 0.351, 95% CI: 0.207-0.495) and 15 LMIc (SDM: 0.426, 95% CI: 0.071-0.780; Figure 4A ). The analysis for intervention period showed that interventions 6 months did not affect the clinical parameters of the patient (P=0.333). In the second group, 6-12 months of pharmacist intervention showed an improved effect, and the patients exhibited 36.4% more mean HbA1c level changes than the UC group (P0.001). The longest intervention period of 12 months exhibited better effect on HbA1c reduction, with 38.8% more change in levels of HbA1c than the UC group (P=0.006; Figure 4B ).
Risk of bias score assessment by ePOC
The quality score of each study was graded by EPOC risk of bias tool by two independent researchers. As the selected primary literature had a low risk of bias in the domain of baseline outcome measure and characteristics, the baseline characteristics between two groups were similar. The reporting of results section had little risk either. However, the risks on blinding, allocation concealment, and contamination were high due to the nature of educational intervention studies (Table S3) .
Publication bias
As widely accepted tools for publication bias, funnel plot visualization and Egger's regression method were used to detect publication bias. Overall, the funnel plot and Egger's regression (P=0.183) methods did not detect publication bias ( Figure S1 ).
Discussion
In this study, we found a significant association between pharmacist-led pharmaceutical care and clinical diabetes management. This finding is corroborated by previous metaanalysis and systematic analysis for cardiovascular disease patients. 11, 12 Well-trained clinical pharmacists and a medical system utilizing active pharmacist-driven patient care can improve the quality, outcomes, and efficiency of patient management. Because this analysis included 20 studies from HIc and 15 from LMIc, the group analysis by income level showed that PC intervention was helpful in improving clinical outcomes in patients with diabetes in both HIc and LMIc. The positive outcomes observed in LMIc are particularly important considering the recent increase in the number of patients with diabetes and metabolic diseases in LMIc. The rapid spread of Western diet and lifestyle, as well as the improvement of socioeconomic status in LMIc, accelerates the incidence of obesity and chronic metabolic diseases in these countries. However, the introduction of clinical PC, such as MTM or multidisciplinary team care, is relatively rare in LMIc compared to that in HIc. A recent review reported that only 12% of clinical PC service is available for drug monitoring activities in Saudi Arabia. 24 Controlling the glucose levels at a recommended level is a difficult task, and therefore, 57% of these patients achieved control of blood glucose as measured by HbA1c concentrations. 25 A meta-analysis by Li et al 14 included 14 RCTs and reported higher mean change in HbA1c (0.68) than that in our study (0.370), and another meta-analysis by Poolsup et al 
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effect of pharmaceutical care on glycemic control included 22 RCTs and reported the same mean change of 0.68 between PC and UC groups. We tried not to include heterogeneous population and excluded the research on adolescents and gestational diabetes patients. We excluded some studies that reported inadequate information to incorporate into meta-analysis that were included in the previous metaanalyses, which might be the reason of the different result. Furthermore, we included additionally 10 recently published studies conducted in LMIc, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and this factor impacted the different results as well.
Generally, the care itself and the social/individual treatment costs of passive medical service administration are challenging. Therefore, more active and interactive multisector collaboration work is essential to manage complicated diseases such as diabetes. In addition, the length of the intervention period is important in achieving adequate effects on clinical parameter improvement.
Another important finding of this study is that the longer intervention period of 6 months showed significant impact on the clinical parameters, while the intervention period of 6 months did not. These factors suggest the need for expanded training in primary care, with at least 6 months of education and intervention, to improve the comprehensiveness and quality of care provided to the growing number of patients with diabetes.
From the aspect of intervention tools, most interventions comprise a face-to-face method between pharmacists and patients, supplemented with leaflets and telephone outreach. The growing information age has enabled the availability of high-technology information and education tool kits. To educate diabetic patients, high-technology investments should be accelerated by country-level funding as suggested by a few studies [36] [37] [38] in which the participants showed a considerable decrease in the HbA1c level and several technological 30 2015 (Jordan), in that all the studies showed promising outcomes for pharmacist-led pharmaceutical care strategy in diabetes care in LMIc. A study evaluating the clinical outcome of blood pressure control reported that after stopping the PC, patient behavior returned to preintervention level, meaning consistent PC care is needed to better contribute to patients' clinical outcome. 39 There are some limitations to our study. The risk of bias evaluated by EPOC guideline showed that some of the included publications lack methodical robust in blinding, allocation concealment, and reporting of contaminations. These factors can be considered in future clinical studies to make the results 
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effect of pharmaceutical care on glycemic control more reliable. The big heterogeneity of included studies is another limitation of this study. This heterogeneity is not from the clinical factor but is derived from statistical or unexplainable factors, so we adopted the random-effects model into the meta-analysis by using a statistic that indicates the percentage of variance in a meta-analysis that is attributable to study heterogeneity (I   2   ) . This model sets an assumption that the effects being estimated in the different studies are not identical but follow some distribution. Even though the random-effects model confronts some criticism but simulations have proven that this method is relatively robust even under wide range of distributional assumptions, both in estimating heterogeneity 40 and calculating an overall effect size. 41 Thus, by using randomeffects model in our analysis, the heterogeneity of included studies has been overcome in our research.
Conclusion
Clinical pharmacists can make a comparative evaluation of medications based on sound knowledge of medications. 
